Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1535-1546

  Jansen, J P ^a   Meis, J F ^b   Blijlevens, N M ^c   Van't Wout, J W ^d  

^a MAPI GROUP   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Invasive aspergillosis; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFTAZIDIME; HYDROCORTISONE; ITRACONAZOLE; MEROPENEM; PARACETAMOL; PETHIDINE; PIPERACILLIN; TAZOBACTAM; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION THEORY; DISEASE COURSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; LIVER TOXICITY; LONG TERM CARE; NEPHROTOXICITY; NETHERLANDS; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; MARKOV CHAINS; NETHERLANDS; PYRIMIDINES; TRIAZOLES;

EID: 27144464907     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65312     Document Type: Article

References (15)

1. Dixon DM, McNeil MM, Cohen ML, et al. Fungal infections: a growing threat. Public Health Rep 1996;111:226-35
2. Lamagni TL, Evans BG, Shigematsu M, et al. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001;126:397-414
3. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32
4. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803
5. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000;30:653-7
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2002;347:408-15
7. Wilson LS, Reyes CM, Stolpman M, et al. The direct costs and incidence of systemic fungal infections. Value in Health 2002;5:26-34
8. Tollemar J, Ringden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf 1995;13:207-18
9. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22
10. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-90
11. Van Dijck JAAM, Coebergh JWW, Siesling S, et al. Trends of cancer in the Netherlands 1989-1998: Report of the Netherlands Cancer Registry. Utrecht: Vereniging van Integrale Kankercentra, 2000
12. Marciniak A, Mauskopf J, Wenzel R, et al. Cost-consequence model for comparing voriconazole with conventional amphotericin B as initial antifungal therapy in the treatment of invasive aspergillosis. Poster presented at the 4th World Congress of the international Health Economics Association, San Francisco, USA June 15-18, 2003
13. Z-Index taxe: selections of the G-standard drug databank. Den Haag:Z-index BV, 2003. Available from http://www.z-index.nl [Accessed 1 February 2005]
14. Central tariffs of consultation and procedures in health care. Utrecht: National Health Tariffs Authority, 2003. Available from http://www.ctgzorg.nl [Accessed 1 February 2005]
15. Oostenbrink JB, Koopmanschap MA, Rutten FF. Manual for cost calculations: methods and recommended prices for economic evaluations in health care. Handleiding voor kostenberekeningen: methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2000